Rumeysa Berra Karataş

Rumeysa Berra Karataş

Auto-generated profile, based on publicly available information

Rumeysa Berra Karataş

Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University , 34015, Istanbul

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2026 in Tissue and Cell
Verified
Journal Article
Closed access
RKRumeysa Berra Karataş
Rumeysa Berra Karataş
ŞDŞevval Dikmen
Şevval Dikmen
EYElçin Yenigül
Elçin Yenigül
PBParisa Bolouri
Parisa Bolouri
FŞFikrettin Şahin
Fikrettin Şahin
EAEsra Aydemir
Esra Aydemir

4 November 2026 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
STSarenur Tekiner
Sarenur Tekiner
YAYaren Alras
Yaren Alras
RKRumeysa Berra Karataş
Rumeysa Berra Karataş
KZKaan Zıkşahna
Kaan Zıkşahna
OEOnur Esen
Onur Esen
MIMURAT IHLAMUR
MURAT IHLAMUR
Objectives: To synthesize current knowledge of the taxonomy, ethnopharmacology, phytochemistry, and pharmacological potential of Anemone sensu lato, including lineages historically treated as Pulsatilla and Hepatica, and assess its relevance to natural-product and drug-discovery research. Methods: Literature in Scopus, Web of Science Core Collection, PubMed, and Google Scholar was reviewed through March 2026. Scientific names and synonymy were verified using the International Plant Names Index and World Flora Online. Key findings: Anemone taxa are traditionally used for inflammatory, infectious, painful, and wound-related conditions and contain abundant triterpenoid saponins, alongside flavonoids, phenolic acids, lactone derivatives, and minor metabolites. Triterpenoid saponins are the predominant bioactive class and are associated with antibacterial, antioxidant, anti-inflammatory, anticancer, hepatoprotective, antidiabetic, and tissue-protective effects in preclinical models. Reported mechanisms involve oxidative stress, inflammatory mediators, apoptosis-related pathways, and proliferative signaling. Translation remains limited by taxonomic ambiguity, interspecific chemical variability, insufficient extract standardization, incomplete pharmacokinetic characterization, and inadequate toxicity assessment. Conclusions: Anemone taxa are promising sources of pharmacologically relevant natural products. Rigorous species authentication, standardized phytochemical profiling, harmonized safety evaluation, and clinically relevant models are required before therapeutic development can be advanced.

6 April 2026 in International Reviews of Immunology
Verified
Journal Article
Closed access
RKRümeysa Berra Karataş
Rümeysa Berra Karataş
FAFurkan Ayaz
Furkan Ayaz
EAEsra Aydemir
Esra Aydemir
Gamma-delta (γδ) T cells, which bridge innate and adaptive immunity, are attractive candidates for immunotherapy. Significant interspecies differences exist, particularly between humans and ruminants. In ruminants, γδ T cells are a major circulating population characterized by the Workshop Cluster 1 (WC1) family, a unique set of Scavenger Receptor Cysteine-Rich (SRCR) co-receptors. WC1 molecules function dually as pattern recognition receptors (PRRs) and essential co-stimulators for the γδ T cell receptor (TCR). Specific WC1 isoforms (e.g. WC1.1+, WC1.2+) are associated with distinct functional predispositions, within a broader functional plasticity observed in both human and murine γδ T cell subsets. This review compares human and ruminant γδ T cell biology, proposing the WC1 co-stimulatory system as a functional paradigm for next-generation human T cell therapies. "WC1-inspired" synthetic receptors could provide more physiological, sustained activation, potentially overcoming key therapeutic limitations such as antigen escape and severe toxicity. Despite translational challenges, including the lack of a direct human WC1 ortholog, the ruminant model provides a critical potential for designing more durable and context-responsive immunotherapies.


15 September 2026 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
STSarenur Tekiner
Sarenur Tekiner
RKRumeysa Berra Karataş
Rumeysa Berra Karataş
YAYaren Alras
Yaren Alras
KZKaan Zıkşahna
Kaan Zıkşahna
SMSelim Merdan
Selim Merdan
MIMURAT IHLAMUR
MURAT IHLAMUR